Nalaganje...
Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis
The mortality effects and risk-benefit profile of low dose rivaroxaban (2.5 mg twice daily) in patients with coronary heart disease are not completely understood. Five randomized controlled trials (26,110 patients) were selected using PubMed and Cochrane library till April 2019. The background antip...
Shranjeno v:
| izdano v: | J Thromb Thrombolysis |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7554154/ https://ncbi.nlm.nih.gov/pubmed/32281069 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11239-020-02114-7 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|